Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107843 | 0.84 | LOXL2 (0.52) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL776520 | 0.84 | LOXL2 (0.57) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL1627332 | 0.84 | TSHR (0.53) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL97944 | 0.84 | LOXL2 (0.52) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL18387801 | 0.82 | LOXL2 (0.50) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL7107845 | 0.82 | LOXL2 (0.50) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL18387787 | 0.82 | TSHR (0.52) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL19398866 | 0.82 | CA2 (0.61) | ALDH1A1HPGDMAPT | |
| SCHEMBL9307922 | 0.81 | LOXL2 (0.58) | LOXL2TSHRALDH1A1IDO1HSD17B10 | |
| SCHEMBL9155804 | 0.81 | LOXL2 (0.48) | LOXL2TSHRALDH1A1IDO1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | BRITISH COLUMBIA CANCER AGENCY BRANCH | 2021-01-05 | — | — | US | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | TEN30 BIOSCIENCES, INC. | 2019-10-29 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | TEN30 BIOSCIENCES, INC. | 2019-04-18 | — | — | US | disclosed |
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180066074-A1 | Colorimetric Hydrogel Based Nanosensor for Detection of Therapeutic Levels of Ionizing Radiation | BANNER HEALTH - AN ARIZONA NONPROFIT CORPORATION | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004043367-A2 | FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | LOXL2 4685/4885TSHR 68/4885ALDH1A1 2745/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | LOXL2 1103/4885TSHR 4486/4885ALDH1A1 1121/4885 |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | KLK3, FOLH1, FOLR1 | LOXL2 3693/4885TSHR 1326/4885ALDH1A1 2768/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | LOXL2 4490/4885TSHR 762/4885ALDH1A1 2970/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | LOXL2 1103/4885TSHR 4486/4885ALDH1A1 1121/4885 |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | APP, PSEN2, PSEN1 | LOXL2 4028/4885TSHR 4495/4885ALDH1A1 4306/4885 |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | APP, PSEN2, PSEN1 | LOXL2 4070/4885TSHR 4386/4885ALDH1A1 4308/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | LOXL2 3128/4885TSHR 3876/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.